The CLEVER Study - Coreg And Left Ventricular Mass Regression

Status Completed

Clinical Trial Summary

This study is designed to compare the effects of COREG MR (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ACE) inhibition, and to the effect of ACE inhibition alone. Subjects with LVH (left ventricular hypertrophy) and hypertension will be studied. The primary endpoint will be the change in left ventricular mass index (LVMI) characterized by magnetic resonance imaging (MRI) following 12 months of treatment. Secondary endpoints include the change in LV (left ventricular) mass, LV wall thickness, diastolic left ventricular filling parameters, and left ventricular ejection fraction by echocardiographic methods at Treatment Month 12. Composite outcomes and individual event data will also be evaluated by treatment group.

Clinical Trial Description

A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00108082
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 3
Start date	January 2005
Completion date	August 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02237339` - Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?	Phase 4
Completed	`NCT00041418` - Cardiac MR of Subclinical CVD: Impact of Age	N/A
Completed	`NCT00005373` - Racial Differences in the Coronary Microcirculation	N/A
Recruiting	`NCT00989508` - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy	Phase 2/Phase 3
Completed	`NCT03482934` - Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate
Completed	`NCT03415750` - Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants	Phase 4
Completed	`NCT02973607` - Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
Completed	`NCT03749551` - Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Completed	`NCT01976689` - New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation	N/A
Enrolling by invitation	`NCT05713916` - Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy	N/A
Recruiting	`NCT00552851` - Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant	Phase 4
Active, not recruiting	`NCT03094143` - Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS	N/A
Completed	`NCT02444689` - EMPower: Electronic Media Powering Positive Health Changes in Youth	N/A
Terminated	`NCT00616902` - The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5	Phase 3
Withdrawn	`NCT03315832` - Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study	Phase 2/Phase 3
Completed	`NCT03180593` - Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH	Phase 4
Completed	`NCT01144039` - Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair	Phase 4
Completed	`NCT00045994` - The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling	Phase 2
Active, not recruiting	`NCT02599480` - Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure	Phase 2
Active, not recruiting	`NCT04862273` - Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis